Pfizer

NYVEPRIA

Manufacturer:

Pfizer

Nyvepria HCPCS:

Q5122

HCPCS Code Descriptor:

Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg

Category:

Q Code

Nyvepria NDCs:

00069-0324-01

Primary Type:

Oncology Biosimilar Colony Stimulating Factor

Generic/Specialty Status:

Single-Source

Package Type:

Syringe

Route of Administration:

Subcutaneous

Nyvepria CPT Codes:

Potential CPT administration codes for Nyvepria can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Nyvepria:

NYVEPRIA is an Oncology Biosimilar Colony Stimulating Factor drug manufactured by Pfizer and administered via the Subcutaneous route of administration. The Q Code: Q5122 is aligned to the drug NYVEPRIA.

Nyvepria (pegfilgrastim) is a man-made protein that aids in the production of certain white blood cells (neutrophils). This medication can be used as a preventative measure to ensure that a patient doesn’t have a deficiency of neutrophils. Nyvepria is produced by Pfizer and is a biosimilar to the medication Neulasta (J2506). Nyvepria has been aligned to the HCPCS code Q5122 since January 2021.

ACCESS PRICING AND MORE BY REGISTERING

Q5122 Added Date:

January 1, 2021

Q5122 Effective Date:

April 1, 2023

Q5122 Termination Date:

HCPCS Active

Nyvepria billing and coding information can be found through Pfizer at the link below:
Nyvepria patient assistance information can be found through Pfizer Oncology Support at the URL: https://nyvepria.pfizerpro.com/support-resources/access-support
NYVEPRIA prescribing information can be found at the link below:
Information regarding NYVEPRIA’s side effects can be found at MedlinePlus